Artículos

Artículos Encontrados 110 registros  inicioanterior22 - 31siguientefinal  ir al registro: La búsqueda tardó 0.00 segundos. 
22.
9 p, 690.9 KB Effectiveness and safety of bisphosphonates therapy in secondary osteoporosis in children Efectividad y seguridad de los bisfosfonatos en el tratamiento de la osteoporosis infantil secundaria / Galindo Zavala, Rocío (Hospital Materno-Infantil de Málaga. Unidad de Pediatría, Sección Reumatología Pediátrica) ; Bou, Rosa (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ; Mir-Perelló, Concepción (Institut d'Investigació Sanitària Illes Balears) ; Martínez Regueira, Soledad (Complejo Hospitalario Universitario de A Coruña) ; Magallares López, Berta Paula (Institut d'Investigació Biomèdica Sant Pau) ; López-Corbeto, Mireia (Hospital Universitari Vall d'Hebron)
Introduction: There are few studies on effectiveness and safety of bisphosphonate therapy in secondary osteoporosis in children. The aim of this research was to analyse effectiveness and safety of bisphosphonates in secondary osteoporosis in children. [...]
2022 - 10.1016/j.anpedi.2021.09.008
Anales de pediatría, Vol. 97 Núm. 3 (septiembre 2022) , p. 190-198  
23.
14 p, 1.9 MB Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients : a randomised controlled trial / Chastre, Jean (Service de Médecine Intensive Réanimation. Institut de Cardiologie. Groupe Hospitalier Pitié-Salpêtrière. Assistance Publique-Hôpitaux de Paris. Sorbonne University) ; François, Bruno (Réanimation Polyvalente and Inserm CIC 1435 & UMR 1092. CHU) ; Bourgeois, Marc (AZ Sint-Jan Brugge-Oostende AV) ; Komnos, Apostolos (General Hospital of Larissa) ; Ferrer, Ricard (Hospital Universitari Vall d'Hebron) ; Rahav, Galia (Chaim Sheba Medical Center. Sackler School of Medicine. Tel Aviv University) ; De Schryver, Nicolas (Clinique Saint-Pierre) ; Lepape, Alain (Hospices Civils de Lyon Hôpital Lyon Sud) ; Koksal, Iftihar (Faculty of Medicine. Trabzon and Acibadem University Faculty of Medicine. Karadeniz Technical University) ; Luyt, Charles-Edouard (Service de Médecine Intensive Réanimation. Institut de Cardiologie. Groupe Hospitalier Pitié-Salpêtrière. Assistance Publique-Hôpitaux de Paris. Sorbonne University) ; Sánchez-García, Miguel (Hospital Clínico San Carlos. Unidad de Cuidados Intensivos) ; Torres, Antoni (Hospital Clínic i Provincial de Barcelona. Servei de Pneumologia) ; Eggimann, Philippe (Department of Locomotor Apparatus. Centre Hospitalier Universitaire Vaudois CHUV) ; Koulenti, Despoina (2nd Critical Care Department. Attikon University Hospital. National and Kapodistrian. University of Athens) ; Holland, Thomas L. (Duke Clinical Research Institute) ; Ali, Omar (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Shoemaker, Kathryn (Respiratory and Immunology. BioPharmaceuticals R&D. AstraZeneca) ; Ren, Pin (Respiratory and Immunology. BioPharmaceuticals R&D. AstraZeneca) ; Sauser, Julien (Infection Control Program. Faculty of Medicine. Geneva University Hospitals) ; Ruzin, Alexey (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Tabor, David E. (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Akhgar, Ahmad (Clinical Pharmacology and Quantitative Pharmacology. Clinical Pharmacology and Safety Sciences. BioPharmaceuticals R&D. AstraZeneca) ; Wu, Yuling (Clinical Pharmacology and Quantitative Pharmacology. Clinical Pharmacology and Safety Sciences. BioPharmaceuticals R&D. AstraZeneca) ; Jiang, Yu (Clinical Pharmacology and Quantitative Pharmacology. Clinical Pharmacology and Safety Sciences. BioPharmaceuticals R&D. AstraZeneca) ; DiGiandomenico, Antonio (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Colbert, Susan (Oncology. US SM&M. AstraZeneca) ; Vandamme, Drieke (Inserm CIC 1435. CHU) ; Coenjaerts, Frank (University Medical Center Utrecht) ; Malhotra-Kumar, Surbhi (University of Antwerp. Laboratory of Medical Microbiology) ; Timbermont, Leen (University of Antwerp. Laboratory of Medical Microbiology) ; Oliver, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Barraud, Olivier (INSERM U1092. Centre Hospitalier Universitaire de Limoges. Université Limoges) ; Bellamy, Terramika (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Bonten, Marc (Julius Center for Health Science and Primary Care. University Medical Center Utrecht. Utrecht University) ; Goossens, Herman (Laboratory of Medical Microbiology. Vaccine and Infectious Disease Institute. University of Antwerp) ; Reisner, Colin (DevPro Biopharma) ; Esser, Mark T. (Clinical Research and Development. Vaccines and Immune Therapies. BioPharmaceuticals R&D. AstraZeneca Biopharmaceuticals) ; Jafri, Hasan S. (Late-Stage Development. Respiratory and Immunology. BioPharmaceuticals R&D. AstraZeneca) ; Joannidis, Michael ; Klimscha, Walter ; De Waele, Elisabeth ; Devriendt, Jacques ; Huberlant, Vincent ; Depuydt, Pieter ; Van Boxstael, Sam ; Peric, Mladen ; Kopic, Jasminka ; Hanauer, Michal ; Hruby, Tomas ; Sramek, Vladimir ; Svoboda, Petr ; Vymazal, Tomas ; Novacek, Martin ; Annane, Djillali ; Mira, Jean-Paul ; Souweine, Bertrand ; Dequin, Pierre-François ; Meziani, Ferhat ; Stephan, François ; Nseir, Saad ; Gibot, Sebastien ; Schwebel, Carole ; Plantefeve, Gaetan ; Diehl, Jean-Luc ; Richard, Christian ; Lamer, Christian ; Klouche, Kada ; Jaber, Samir ; Zakynthinos, Epaminondas ; Filntisis, Georgios ; Zakynthinos, Spyros ; Koutsoukou, Antonia ; Saroglou, Georgios ; Nikolaou, Charikleia ; Vlachogianni, Glykeria ; Pnevmatikos, Ioannis ; Mandragos, Konstantinos ; Kremer, Ildiko ; Rozgonyi, Zsolt Dezso ; Marjanek, Zsuzsa ; Martin-Loeches, Ignacio ; Singer, Pierre ; Van Heerden, Vernon ; Carmeli, Yehuda ; Povoa, Pedro ; AlvarezSeoane, Antonio ; Moura, Pedro ; Gonzalez, Filipe ; Ramirez, Paula ; Torres Marti, Antonio ; Ferrer Roca, Ricard ; Oteiza, Lorena ; Escudero, Dolores ; Piacentini, Enrique ; Vera-Artazcoz, Paula (Institut d'Investigació Biomèdica Sant Pau) ; Tamayo, Luis ; Gonzalez Gallego, Miguel Angel ; Suberviola Canas, Borja ; Figueira, Iglesias ; Leon, Rafael ; Korten, Volkan ; Akova, Murat ; Wyncoll, Duncan ; Whitehouse, Tony ; Hopkins, Phil ; Sim, Malcolm ; Golan, Yoav ; Zervos, Marcus ; Vazquez, Jose ; Cherabuddi, Kartikeya ; Smulian, George ; Rouphael, Nadine ; Welker, James ; Sims, Mathew ; Van Duin, David ; McCarthy, Todd ; Polk, Christopher
Background: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised mechanically ventilated subjects. [...]
2022 - 10.1186/s13054-022-04204-9
Critical Care, Vol. 26 Núm. 1 (december 2022) , p. 355  
24.
19 p, 1.1 MB Vortioxetine in major depressive disorder : from mechanisms of action to clinical studies. An updated review / de Diego-Adeliño, Javier (Institut d'Investigació Biomèdica Sant Pau) ; Crespo, José Manuel (Complejo Hospitalario Universitario de Ferrol) ; Mora, Fernando (Hospital Universitario Infanta Leonor) ; Neyra, Adrián (Hospital Universitario de Gran Canaria Dr. Negrín) ; Iborra, Pedro (Hospital Universitario San Juan de Alicante) ; Gutiérrez-Rojas, Luis (Hospital Universitario San Cecilio (Granada)) ; Salonia, Selman F. (Centro de Salud Mental de Jumilla) ; Universitat Autònoma de Barcelona
Introduction: Vortioxetine is a multimodal-acting antidepressant that provides improvements on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has been found to be one of the most effective and best tolerated options for major depressive disorder (MDD) in head-to-head trials. [...]
2022 - 10.1080/14740338.2022.2019705
Expert Opinion on Drug Safety, Vol. 21 Núm. 5 (2022) , p. 673-690  
25.
11 p, 1.1 MB Safety of cladribine tablets in the treatment of patients with multiple sclerosis : An integrated analysis / Cook, Stuart (Rutgers. The State University of New Jersey) ; Leist, Thomas (Jefferson University) ; Comi, Giancarlo (Università Vita-Salute San Raffaele) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Giovannoni, Gavin (Queen Mary University of London) ; Nolting, Axel (Merck KGaA) ; Hicking, Christine (Merck KGaA) ; Galazka, Andrew (Merck. Zone Industrielle de L'Ouriettaz) ; Sylvester, Elke (Merck KGaA) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Treating patients with relapsing multiple sclerosis (MS) with cladribine tablets (two times 4 or 5 days of treatment each year for 2 years) results in long-lasting efficacy, with continued stability in many patients for 4 or more years. [...]
2019 - 10.1016/j.msard.2018.11.021
Multiple Sclerosis and Related Disorders, Vol. 29 (april 2019) , p. 157-167  
26.
8 p, 915.8 KB Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis / Leist, Thomas (Jefferson University) ; Cook, S. (New Jersey Medical School) ; Comi, Giancarlo (Università Vita-Salute San Raffaele) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Giovannoni, Gavin (Queen Mary University of London) ; Nolting, A. (Merck KGaA) ; Damian, D. (Merck KGaA) ; Syed, S. (Merck KGaA) ; Galazka, Andrew (Merck KGaA) ; Universitat Autònoma de Barcelona
Background: Long-term safety data are of particular interest for any newly approved treatment in multiple sclerosis such as cladribine tablets 10 mg (MAVENCLAD®; 3. 5 mg/kg cumulative dose over 2 years, referred to as cladribine tablets 3. [...]
2020 - 10.1016/j.msard.2020.102572
Multiple Sclerosis and Related Disorders, Vol. 46 (november 2020) , p. 102572  
27.
10 p, 683.9 KB Ozanimod in relapsing multiple sclerosis : Pooled safety results from the clinical development program / Selmaj, Krzysztof W. (University of Warmia and Mazury) ; Cohen, Jeffrey A. (Neurological Institute) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Bar-Or, Amit (University of Pennsylvania) ; Arnold, Douglas Lorne (McGill University) ; Steinman, Lawrence (Stanford University Medical Center) ; Hartung, Hans-Peter (Medical University Vienna) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Kubala Havrdova, Eva (Charles University) ; Cree, Bruce A. C (UCSF University of California San Francisco) ; Minton, Neil (Bristol Myers Squibb) ; Sheffield, James K. (Bristol Myers Squibb) ; Ding, Ning (Bristol Myers Squibb) ; Kappos, Ludwig (University of Basel) ; Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for the treatment of relapsing multiple sclerosis (RMS). In phase 3 trials, ozanimod was well tolerated and superior to interferon beta-1a 30 µg once-weekly in reducing clinical and radiologic disease activity. [...]
2021 - 10.1016/j.msard.2021.102844
Multiple Sclerosis and Related Disorders, Vol. 51 (june 2021) , p. 102844  
28.
16 p, 2.3 MB Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España / Meca-Lallana, Jose Eustasio (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ; Fernández-Prada, M. (Hospital Vital Álvarez-Buylla) ; García Vázquez, E. (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ; Moreno Guillén, S. (Hospital Universitario Ramón y Cajal (Madrid)) ; Otero-Romero, Susana (Hospital Universitari Vall d'Hebron) ; Rus Hidalgo, M. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Villar Guimerans, L. M. (Hospital Universitario Ramón y Cajal (Madrid)) ; Eichau Madueño, S. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Fernández Fernández, Ó. (Hospital Regional Universitario de Málaga) ; Izquierdo Ayuso, G. (Hospital Vithas Nisa) ; Alvarez-Cermeño, José C (Hospital Universitario Ramón y Cajal (Madrid)) ; Arnal García, C. (Hospital Universitario Virgen de las Nieves (Granada)) ; Arroyo, Rafael (Grupo Quirónsalud (Madrid, Espanya)) ; Brieva Ruiz, Luis (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Calles, Carmen (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; García Merino, A. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; González Platas, M. (Hospital Universitario de Canarias (La Laguna)) ; Hernández Pérez, M. Á. (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ; Moral Torres, E. (Hospital de Sant Joan Despí Moisès Broggi) ; Olascoaga Urtaza, J. (Hospital Universitario Donostia-Instituto de Investigación BIODONOSTIA) ; Oliva-Nacarino, P. (Hospital Universitario Central de Asturias) ; Oreja-Guevara, Celia (Hospital Clínico San Carlos (Madrid)) ; Ortiz Castillo, R. (Sanofi-Genzyme) ; Oterino, A. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Prieto González, J. M. (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ; Ramió-Torrentà, Lluís (Hospital Universitari de Girona Doctor Josep Trueta) ; Rodríguez-Antigüedad, A. (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Saiz, A. (Hospital Clínic i Provincial de Barcelona) ; Tintoré, Mar (Hospital Universitari Vall d'Hebron) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron)
Introducción: Alemtuzumab es un fármaco de alta eficacia aprobado por la Agencia Europea de Medicamentos como tratamiento modificador de la enfermedad en pacientes con esclerosis múltiple remitente recurrente. [...]
Introduction: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis. Objective: A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain. [...]

2022 - 10.1016/j.nrl.2019.11.003
Neurología, Vol. 37 Núm. 8 (2022) , p. 615-630
2 documentos
29.
52 p, 190.8 KB Cambios en la política de seguridad vial en España entre 2004 y 2010 : Un análisis centrado en el diseño institucional / Tena Sánchez, Jordi (Universitat Autònoma de Barcelona. Departament de Sociologia)
En el presente trabajo se llevará a cabo un repaso sin ánimo de exhaustividad de los cambios más destacados que se han producido en la política de seguridad vial en España desde el 2004 hasta nuestros días desde la perspectiva del diseño institucional. [...]
In this work, I will review the most important changes carried out in Spanish road safety policies since 2004 from the point of view of institutional design. I argue road safety policy had been erratic in Spain. [...]

2010 - 10.18543/ed-58(2)-2010pp247-298
Estudios de Deusto, Vol. 58 Núm. 2 (julio 2010) , p. 247-298  
30.
12 p, 850.9 KB Characteristics of drug safety alerts issued by the Spanish Medicines Agency / Montané Esteva, Eva (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Santesmases, Javier (Universitat Autònoma de Barcelona. Departament de Medicina)
Objectives: To describe the characteristics of safety alerts issued by the Spanish Medicines Agency (AEMPS) and the Spanish Pharmacovigilance System over a 7-year period and the regulatory actions they generated. [...]
2023 - 10.3389/fphar.2023.1090707
Frontiers in Pharmacology, Vol. 14 (january 2023)  
31.
15 p, 1.6 MB Uptake and Survival of African Swine Fever Virus in Mealworm (Tenebrio molitor) and Black Soldier Fly (Hermetia illucens) Larvae / Olesen, Ann Sofie (Statens Serum Institut. Department of Virus & Microbiological Special Diagnostics) ; Lazov, Christina Marie (University of Copenhagen. Department of Veterinary and Animal Sciences) ; Lecocq, Antoine (University of Copenhagen. Department of Plant and Environmental Sciences) ; Accensi Alemany, Francesc (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals) ; Jensen, Annette Bruun (University of Copenhagen. Department of Plant and Environmental Sciences) ; Lohse, Louise (Statens Serum Institut. Department of Virus & Microbiological Special Diagnostics) ; Rasmussen, Thomas Bruun (Statens Serum Institut. Department of Virus & Microbiological Special Diagnostics) ; Belsham, Graham J. (University of Copenhagen. Department of Veterinary and Animal Sciences) ; Bøtner, Anette (University of Copenhagen. Department of Veterinary and Animal Sciences)
Insect production offers a sustainable source of nutrients for livestock. This comes with a risk for transmission of pathogens from the insects into the livestock sector, including viruses causing serious diseases, such as African swine fever virus (ASFV), classical swine fever virus and foot-and-mouth disease virus. [...]
2022 - 10.3390/pathogens12010047
Pathogens, Vol. 12 (december 2022)  

Artículos : Encontrados 110 registros   inicioanterior22 - 31siguientefinal  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.